An abundance of events are afoot around the world to mark Rare Disease Day 2020 on Feb. 29. The activities are focused on heightening awareness about rare diseases and the hundreds of millions of individuals they are thought to affect. Patients, caregivers, and advocates worldwide will sport denim ribbons…
Oral delivery of two proteins produced on lettuce leaves and involved in blood vessel health eased pulmonary hypertension and heart abnormalities in a rat model of pulmonary arterial hypertension (PAH). These results point to this plant-based approach as a potentially safe, inexpensive, shelf-stable treatment for PAH. Further studies…
Vitamin C deficiency can cause pulmonary arterial hypertension (PAH), a new case report suggests, highlighting the need to test vitamin C levels in people with PAH. The report, “Vitamin C Deficiency-Induced Pulmonary Arterial Hypertension,” was published in the journal CHEST. The study details the case of…
The buildup in the lungs and plasma of oxidized low-density lipoproteins, or LDLs — one of the major vehicles for the transport of cholesterol and other types of fatty molecules in the body — is associated with the progression of pulmonary hypertension (PH), a study reports. However,…
Aria CV‘s medical device for treating pulmonary hypertension (PH) has been given a Breakthrough Device designation by the United States Food and Drug Administration (FDA). The Aria CV PH System is designed to reduce the symptoms associated with PH — a condition that develops due to…
The U.S. Food and Drug Administration (FDA), a vast government bureaucracy, employs about 17,500 people and had a budget of $5.7 billion in 2019. Yet even with its enormous resources, the FDA these days relies more and more on patients to…
Switching from injectable treprostinil or epoprostenol to a combination therapy including inhaled treprostinil appears to be safe, well tolerated, and effective for a select group of patients with clinically stable pulmonary arterial hypertension (PAH), a study suggests. The study, “Ambulatory Transition from Parenteral Prostanoid…
The biopharmaceutical PhaseBio announced positive results from a case study involving a patient with pulmonary arterial hypertension (PAH) who received treatment with PB1046, a new therapy using the company’s proprietary technology platform. PB1046…
The gleaming new Dutch headquarters of the European Medicines Agency (EMA), fronting Domenico Scarlattilaan in Amsterdam’s suburban Zuidas business district, finally opened for business last month — just over two years after the European Union decided to relocate the EMA to the Netherlands in the wake of Brexit.
Seeking to further advance research into treatments for pulmonary hypertension (PH), the nonprofit Team PHenomenal Hope is now accepting submissions for its research award program. Called the PHenomenal Impact Fund for Global PH Research, the program supports investigations in basic or translational science, clinical research, and clinical…
Liquidia Technologies is requesting U.S. Food and Drug Administration (FDA) approval of LIQ861, an inhaled dry powder formulation of the vasodilator treprostinil, to treat pulmonary arterial hypertension (PAH). The request came in the form of a new drug application (NDA) to the agency. LIQ861…
Treatment with sotatercept (ACE-011) eased heart strain and improved exercise capacity in individuals with pulmonary arterial hypertension (PAH) participating in the Phase 2 PULSAR trial, according to Acceleron Pharma, the therapy’s manufacturer. Sotatercept is an investigational compound designed to bind and entrap proteins…
Get regular updates to your inbox.